These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 28605730)

  • 1. Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
    Yamamura J; Masuda N; Yamamoto D; Tsuyuki S; Yamaguchi M; Tanaka S; Tsurutani J; Tokunaga S; Yoshidome K; Mizutani M; Aono T; Ooe A; Tanino H; Matsunami N; Yasojima H; Nakayama T; Nishida Y
    Chemotherapy; 2017; 62(5):307-313. PubMed ID: 28605730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
    Schmid P; Heilmann V; Schulz CO; Dieing A; Lehenbauer-Dehm S; Jehn C; Sezer O; Possinger K; Flath B
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):568-74. PubMed ID: 16044345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
    Gómez HL; Neciosup S; Tosello C; Mano M; Bines J; Ismael G; Santi PX; Pinczowski H; Nerón Y; Fanelli M; Fein L; Sampaio C; Lerzo G; Capó A; Zarba JJ; Blajman C; Varela MS; Martínez-Mesa J; Werutsky G; Barrios CH
    Clin Breast Cancer; 2016 Feb; 16(1):38-44. PubMed ID: 26642810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    He K; Wang X; Guan X; Yu Q; Ma Q; Liu Z; Yu Z
    Anticancer Res; 2017 Oct; 37(10):5647-5653. PubMed ID: 28982882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.
    Sanal SM; Gokmen E; Karabulut B; Sezgin C
    Breast J; 2002; 8(3):171-6. PubMed ID: 12047474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
    Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
    Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
    Medioni J; Huchon C; Le Frere-Belda MA; Hofmann H; Bats AS; Eme D; Andrieu JM; Oudard S; Lecuru F; Levy E
    Drugs R D; 2011; 11(2):147-57. PubMed ID: 21679005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial.
    Gioulbasanis I; Saridaki Z; Kalykaki A; Vamvakas L; Kalbakis K; Ignatiadis M; Amarantidis K; Kakolyris S; Georgoulias V; Mavroudis D
    Anticancer Res; 2008; 28(5B):3019-25. PubMed ID: 19031950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
    Martín M; Ruiz A; Muñoz M; Balil A; García-Mata J; Calvo L; Carrasco E; Mahillo E; Casado A; García-Saenz JA; Escudero MJ; Guillem V; Jara C; Ribelles N; Salas F; Soto C; Morales-Vasquez F; Rodríguez CA; Adrover E; Mel JR;
    Lancet Oncol; 2007 Mar; 8(3):219-25. PubMed ID: 17329192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
    Nicolaides C; Dimopoulos MA; Samantas E; Bafaloukos D; Kalofonos C; Fountzilas G; Razi E; Kosmidis P; Pavlidis N
    Ann Oncol; 2000 Jul; 11(7):873-5. PubMed ID: 10997817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Dong N; Wang M; Li H; Cui Y; Guo Q
    Cancer Chemother Pharmacol; 2012 May; 69(5):1315-22. PubMed ID: 22307763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
    Morabito A; Filippelli G; Palmeri S; Cascinu S; Ferraù F; Zagonel V; Gattuso D; Catalano V; Capaccetti B; Franciosi V; Accurso V; Scinto F; Gasparini G
    Breast Cancer Res Treat; 2003 Mar; 78(1):29-36. PubMed ID: 12611454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
    Morabito A; Longo R; Gattuso D; Carillio G; Massaccesi C; Mariani L; Bonginelli P; Amici S; De Sio L; Fanelli M; Torino F; Bonsignori M; Gasparini G
    Oncol Rep; 2006 Aug; 16(2):393-8. PubMed ID: 16820921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
    Zhou NN; Teng XY; Jiang WQ; Liu DG
    Ai Zheng; 2007 Dec; 26(12):1373-6. PubMed ID: 18076805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
    Park IH; Ro J; Lee KS; Kim SN; Yun YH; Nam BH
    Invest New Drugs; 2010 Oct; 28(5):659-69. PubMed ID: 19575146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
    Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
    J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain.
    Colomer R; Llombart-Cussac A; Tusquets I; Rifà J; Mayordomo JI; Ojeda B; Ciruelos E; Hornedo J; Vicente D; Cortés-Funes H
    Clin Transl Oncol; 2006 Dec; 8(12):896-902. PubMed ID: 17169763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.